All these trials are investigating proton therapy with anti-PD-1 or anti-PD-L1 safety and efficacy for metastatic cancers (neoplasm or head and neck), non-small cell lung cancer, head and neck cancer or meningioma. Here, CD274 is linked to metastatic malignant neoplasm.